Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 433

1.

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.

Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, Zhang S.

J Transl Med. 2013 Sep 17;11:215. doi: 10.1186/1479-5876-11-215.

2.

PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.

Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S.

PLoS One. 2014 Feb 27;9(2):e89350. doi: 10.1371/journal.pone.0089350. eCollection 2014.

3.

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.

Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X.

J Transl Med. 2014 Feb 7;12:36. doi: 10.1186/1479-5876-12-36.

4.

Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.

Guo Z, Wang H, Meng F, Li J, Zhang S.

J Transl Med. 2015 Jul 29;13:247. doi: 10.1186/s12967-015-0613-y.

5.

Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin.

Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE, Guo Y.

PLoS One. 2013 Dec 19;8(12):e84927. doi: 10.1371/journal.pone.0084927. eCollection 2013.

6.

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.

Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, Hellstrom I, Hellstrom KE.

J Immunother. 2013 May;36(4):248-57. doi: 10.1097/CJI.0b013e3182943549.

7.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

8.

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.

Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazón A, Azpilikueta A, Ochoa MC, Alfaro C, Solano S, Pérez-Gracia JL, Oyajobi BO, Melero I.

Clin Cancer Res. 2008 Nov 1;14(21):6895-906. doi: 10.1158/1078-0432.CCR-08-0285.

9.

Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.

Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, Kakimi K.

J Immunother. 2012 Jul;35(6):460-72. doi: 10.1097/CJI.0b013e31826092db.

PMID:
22735804
10.

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.

Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP.

PLoS One. 2011 Apr 29;6(4):e19499. doi: 10.1371/journal.pone.0019499.

11.

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H.

Clin Cancer Res. 2010 May 15;16(10):2781-91. doi: 10.1158/1078-0432.CCR-09-3243. Epub 2010 May 11.

12.

4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.

Lee J, Lee EN, Kim EY, Lee HJ, Park HJ, Sun CL, Lee SK, Joh JW, Lee KW, Kwon GY, Kim SJ.

Transplant Proc. 2005 Jan-Feb;37(1):123-5.

PMID:
15808569
13.

Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.

Duraiswamy J, Freeman GJ, Coukos G.

Cancer Res. 2013 Dec 1;73(23):6900-12. doi: 10.1158/0008-5472.CAN-13-1550. Epub 2013 Aug 23.

14.

Tim-1 blockade with RMT1-10 increases T regulatory cells and prolongs the survival of high-risk corneal allografts in mice.

Tan X, Jie Y, Zhang Y, Qin Y, Xu Q, Pan Z.

Exp Eye Res. 2014 May;122:86-93. doi: 10.1016/j.exer.2014.02.019. Epub 2014 Mar 5.

PMID:
24613782
15.

Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.

Tongu M, Harashima N, Tamada K, Chen L, Harada M.

Cancer Sci. 2015 Jan;106(1):9-17. doi: 10.1111/cas.12568. Epub 2014 Dec 9.

17.

Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.

Gauttier V, Judor JP, Le Guen V, Cany J, Ferry N, Conchon S.

Int J Cancer. 2014 Dec 15;135(12):2857-67. doi: 10.1002/ijc.28943. Epub 2014 May 23.

18.

Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory.

Park JJ, Anand S, Zhao Y, Matsumura Y, Sakoda Y, Kuramasu A, Strome SE, Chen L, Tamada K.

Cancer Immunol Immunother. 2012 Feb;61(2):203-14. doi: 10.1007/s00262-011-1101-8. Epub 2011 Aug 30.

19.

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.

Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M.

Cancer Immunol Immunother. 2013 Apr;62(4):629-37. doi: 10.1007/s00262-012-1371-9. Epub 2012 Nov 10.

PMID:
23143694
20.

CD137-mediated immunotherapy for allergic asthma.

Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hansen G.

J Clin Invest. 2006 Apr;116(4):1025-36. Epub 2006 Mar 9.

Items per page

Supplemental Content

Write to the Help Desk